RVTY vs. AVTR, BIO, ILMN, BIO.B, WAT, VTRS, NTRA, TECH, FMS, and THC
Should you be buying Revvity stock or one of its competitors? The main competitors of Revvity include Avantor (AVTR), Bio-Rad Laboratories (BIO), Illumina (ILMN), Bio-Rad Laboratories (BIO.B), Waters (WAT), Viatris (VTRS), Natera (NTRA), Bio-Techne (TECH), Fresenius Medical Care (FMS), and Tenet Healthcare (THC). These companies are all part of the "medical" sector.
Avantor (NYSE:AVTR) and Revvity (NYSE:RVTY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
Revvity has lower revenue, but higher earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.
Avantor presently has a consensus price target of $26.71, suggesting a potential upside of 6.90%. Revvity has a consensus price target of $118.17, suggesting a potential upside of 7.20%. Given Avantor's higher possible upside, analysts plainly believe Revvity is more favorable than Avantor.
Revvity has a net margin of 5.49% compared to Revvity's net margin of 3.79%. Revvity's return on equity of 13.01% beat Avantor's return on equity.
95.1% of Avantor shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 1.5% of Avantor shares are owned by insiders. Comparatively, 0.6% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Avantor has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Revvity has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
In the previous week, Avantor had 6 more articles in the media than Revvity. MarketBeat recorded 11 mentions for Avantor and 5 mentions for Revvity. Avantor's average media sentiment score of 1.77 beat Revvity's score of 1.20 indicating that Revvity is being referred to more favorably in the news media.
Avantor received 156 more outperform votes than Revvity when rated by MarketBeat users. Likewise, 63.64% of users gave Avantor an outperform vote while only 54.55% of users gave Revvity an outperform vote.
Summary
Avantor beats Revvity on 11 of the 18 factors compared between the two stocks.
Get Revvity News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVTY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVTY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
